Barba Marta, Di Taranto Giuseppe, Lattanzi Wanda
a Institute of Anatomy and Cell Biology , Università Cattolica del Sacro Cuore , Rome , Italy.
b Department of Plastic, Reconstructive and Aesthetic Surgery , University of Rome "Sapienza" , Policlinico Umberto I, Rome , Italy.
Expert Opin Biol Ther. 2017 Jun;17(6):677-689. doi: 10.1080/14712598.2017.1315403. Epub 2017 Apr 13.
Cell-based therapies exploit the heterogeneous and self-sufficient biological environment of stem cells to restore, maintain and improve tissue functions. Adipose-derived stem cells (ASCs) are, to this aim, promising cell types thanks to advantageous isolation procedures, growth kinetics, plasticity and trophic properties. Specifically, bone regeneration represents a suitable, though often challenging, target setting to test and apply ASC-based therapeutic strategies. Areas covered: ASCs are extremely plastic and secrete bioactive peptides that mediate paracrine functions, mediating their trophic actions in vivo. Numerous preclinical studies demonstrated that ASCs improve bone healing. Clinical trials are ongoing to validate the clinical feasibility of these approaches. This review is intended to define the state-of-the-art on ASCs, encompassing the biological features that make them suitable for bone regenerative strategies, and to provide an update on existing preclinical and clinical applications. Expert opinion: ASCs offer numerous advantages over other stem cells in terms of feasibility of clinical translation. Data obtained from in vivo experimentation are encouraging, and clinical trials are ongoing. More robust validations are thus expected to be achieved during the next few years, and will likely pave the way to optimized patient-tailored treatments for bone regeneration.
基于细胞的疗法利用干细胞异质性和自给自足的生物学环境来恢复、维持和改善组织功能。脂肪来源干细胞（ASC）由于其有利的分离程序、生长动力学、可塑性和营养特性，是实现这一目标的有前景的细胞类型。具体而言，骨再生是测试和应用基于ASC的治疗策略的一个合适但往往具有挑战性的目标。涵盖领域：ASC具有极强的可塑性，能分泌介导旁分泌功能的生物活性肽，在体内发挥其营养作用。众多临床前研究表明，ASC可促进骨愈合。目前正在进行临床试验以验证这些方法的临床可行性。本综述旨在界定ASC的最新研究状况，包括使其适用于骨再生策略的生物学特性，并提供现有临床前和临床应用的最新信息。专家观点：在临床转化的可行性方面，ASC比其他干细胞具有诸多优势。从体内实验获得的数据令人鼓舞，临床试验正在进行。因此，预计在未来几年将实现更有力的验证，这可能会为优化的骨再生患者定制治疗铺平道路。
